OPM Announces Its 2022 Annual Results and Provides an Update

OPM Announces Its 2022 Annual Results and Provides an Update on Its Clinical Developments

Revenues and operating income in 2022 of €8.3 M (+110% vs. 2021 proforma), including revenues of €8 M, mainly driven by a €7 M milestone and a €0.5 M up-frontNet income almost at break-even (€0.2) MStrong financial visibility with a cash position of €13.4 M ensuring the development of our programs for the coming yea...

Related Keywords

Philippe Genne , Arthur Rouill , Karine Lignel , Jan Hoflack , Mathilde Bohin Alban Dufumier , Research Tax Credit , Transition Service Agreement , Oncodesign Services , Regulatory News , Precision Medicine , Chief Executive Officer , Oncodesign Biotechnology , Euronext Growth , Artificial Intelligence , Monday April , Ordinary General Meeting , Oncodesign Precision Medicine , Alban Dufumier ,

© 2025 Vimarsana